

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **JBM (HEALTHCARE) LIMITED**

**健倍苗苗(保健)有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**Stock Code: 2161**

### **RESIGNATION OF EXECUTIVE DIRECTOR AND CHANGE OF COMPANY SECRETARY AND AUTHORISED REPRESENTATIVE**

#### **RESIGNATION OF EXECUTIVE DIRECTOR**

The board of directors (the “**Board**”) of JBM (Healthcare) Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) announces that Dr. Chu Ka Wing (“**Dr. Chu**”) has resigned as an executive director of the Company, the president of the proprietary Chinese medicine business of the Group and an authorised representative of the Company (“**Authorised Representative**”) for the purpose of Rule 3.05 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) with effect from 19 March 2022 in order to devote more time for his family and his personal development.

Dr. Chu has confirmed that he has no disagreement with the Board and there are no matters in relation to his resignation that need to be brought to the attention of the Stock Exchange and the shareholders of the Company.

#### **CHANGE OF COMPANY SECRETARY**

The Board announces that Miss Au Man Yee, Teresa (“**Ms. Au**”) has resigned as the company secretary of the Company, and Mr. Lam Kau Lap (“**Mr. Lam**”) has been appointed, as the company secretary of the Company with effect from 19 March 2022.

Ms. Au has confirmed that she has no disagreement with the Board and there are no matters in relation to her resignation that need to be brought to the attention of the Stock Exchange and the shareholders of the Company.

## **Biographical details of Mr. Lam**

Mr. Lam Kau Lap, aged 35, is the Vice President of Finance of the Company and is mainly responsible for the management of the finance and accounting and company secretarial functions of the Group. He has over 10 years of experience in auditing, accounting and finance fields.

He joined the group of Jacobson Pharma Corporation Limited (stock code: 2633), being a controlling shareholder of the Company, in January 2015 as the finance manager, and was later promoted to deputy financial controller in May 2019. He was re-designated as the Group Financial Controller of the Group in July 2020 and resigned in April 2021. He then re-joined the Group in February 2022.

Mr. Lam obtained a bachelor's degree in Business Administration in Accounting and Finance from the University of Hong Kong in June 2008. He has been a member of the Hong Kong Institute of Certified Public Accountants since September 2011.

## **CHANGE OF AUTHORISED REPRESENTATIVE**

The Board further announces that Mr. Lam, the Vice President of Finance and Company Secretary of the Company, has been appointed as an Authorised Representative of the Company to fill the vacancy arising from the resignation of Dr. Chu with effect from 19 March 2022.

The Board would like to take this opportunity to express its sincere gratitude to Dr. Chu and Ms. Au for their valuable contributions to the Company during their tenure of office, and express its warm welcome to Mr. Lam on his new appointment.

By Order of the Board  
**JBM (Healthcare) Limited**  
**Wong Yat Wai, Patrick**  
*Executive Director and Chief Executive Officer*

Hong Kong, 18 March 2022

*As at the date of this announcement (subsequent to the above changes become effective), the Board comprises Mr. Sum Kwong Yip, Derek as the Chairman and non-executive Director, Mr. Wong Yat Wai, Patrick (also as Chief Executive Officer) as executive Director, Mr. Yim Chun Leung and Mr. Yeung Kwok Chun, Harry as non-executive Directors, and Mr. Chan Kam Chiu, Simon, Mr. Luk Ting Lung, Alan and Mr. Lau Shut Lee, Tony as independent non-executive Directors.*